New Issue: Orbital Catastrophe Ahead? Read Now

Scientists Use Bioengineered Yeast Instead of Poppies to Make Opioids

The speedy method makes potent painkilling opioids, but it still must be fine-tuned to make it commercially viable

Join Our Community of Science Lovers!

By Will Dunham

WASHINGTON (Reuters) - Scientists have invented a speedy method to make potent painkilling opioids using bioengineered baker's yeast instead of poppies, but need to fine-tune the process to make it commercially viable, according to a study published on Thursday.

The new method, if it can be made more efficient, could significantly change the multibillion-dollar pain medication manufacturing business, but raises concerns about aggravating the growing problem of opioid abuse.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


This same type of approach potentially also could be used to make other currently plant-based medicines for fighting cancer, infectious diseases and chronic illnesses.

A similar "synthetic biology" technique is already used to make artemisenin, a key malaria-drug ingredient that was previously derived from trees (see Reuters story of August 12, 2014, http://reut.rs/1J2OVkJ).

The scientists said they altered the yeast's genetic make-up in a way that coaxed the cells to convert sugar into two opioids - hydrocodone and thebaine - in three to five days.

"This is important because, with further development, it may provide an alternative supply for these essential medicines and allow greater access for most of the global population that currently has insufficient access to pain medication," said Stanford University bioengineering professor Christina Smolke, who led the research published in the journal Science.

The researchers said they recognized their findings on a quicker process to make opioids could generate concern about worsening the growing abuse of these painkillers.

Smolke's team inserted DNA into the yeast that encodes instructions for the cells to make the enzymes necessary to perform the sugar conversion steps.

The baker's yeast was engineered with 23 genes from six different organisms: the brown rat, the goldthread herb, the California poppy, the Iranian poppy, the opium poppy and a soil bacterium called Pseudomonas putida.

The process unveiled by Smolke's team represents "proof of principle experiments" showing that the bioengineered yeast can produce small amounts of opioid painkillers from scratch, Smolke said. Currently, about 4,400 gallons of bioengineered yeast would be needed to yield a single dose of the medication.

Smolke said the process needs to be improved to make it efficient enough for commercial production, saying this could take several years.

Stanford University holds the patents on the technology described by the researchers, who have formed a company to pursue the commercial applications.

SOURCE: http://bit.ly/1JfsTS7

Science 2015.

 

 

 

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe